Trinity Biotech(US:TRIB) Globenewswire·2025-12-23 13:50Core Viewpoint - Trinity Biotech plc has entered into agreements with Perceptive Advisors to enhance its financial flexibility and optimize its capital structure, supporting ongoing and future growth projects [1][2]. Financial Capacity and Operational Flexibility - The transactions strengthen Trinity Biotech's financial capacity and operational flexibility, enabling continued investment in strategic growth priorities and reinforcing its ability to deliver advanced diagnostic and diabetes management solutions [2][3]. - The agreements position Trinity Biotech to advance its long-term growth agenda while supporting a reduction in overall debt levels [2]. Overview of the Transactions - The agreements reflect a positive relationship between Trinity Biotech and Perceptive Advisors, underscoring their support for the Company's strategy and operational momentum [3]. Financial Summary - The Second Amendment to the Credit Agreement extends the maturity to early 2027 and provides increased near-term funding [6]. - New term-loan proceeds of $5 million will strengthen liquidity for key strategic development initiatives, including the continuous glucose monitoring solution, CGM+ [7]. - Up to $60 million in elective equitization capacity under the term-loan may allow for significant debt and cash interest cost reductions [7]. - Equity settlement mechanisms for milestone payments and contingent obligations are designed to reduce cash requirements [7]. Management Commentary - The CEO of Trinity Biotech stated that these developments place the company in a stronger strategic position to accelerate its innovation agenda, particularly in diabetes management and diagnostics [8].